Ezetimibe, a new cholesterol absorption inhibitor, appears safe and effective for lowering low density lipid cholesterol and improving other key lipid parameters.
Carlos A. Dujovne, MD, at the Kansas Foundation for Clinical Pharmacology, Overland Park, Kansas, United States, and colleagues conducted a randomised, double-blind, placebo-controlled trial to evaluate the safety and efficacy of the new drug.
The study involved 892 patients with primary hypercholesterolemia, with low density lipid (LDL) cholesterol levels between 130 to 250 mg/dL and triglycerides at 350 mg/dL or less. After two weeks on the National Cholesterol Education Program (NCEP) Step I or a stricter diet, and a four- to eight-week single-blind placebo lead-in, the patients were randomised 3-1 to receive ezetimibe 10 mg or placebo orally each morning for 12 weeks.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!